- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00784446
First-line Therapy of Stage IV Colorectal Cancer
January 4, 2013 updated by: Ulrich Hacker, University of Cologne
A Phase I/II Study of Capecitabine/Oxaliplatin (XELOX) in Combination With Bevacizumab and Imatinib as First-line Treatment of Patients With Stage IV Colorectal Cancer
Assessment of safety and toxicity, definition of the dose limiting toxicity (DLT) of the combination therapy consisting of Capecitabine, Oxaliplatin, Bevacizumab and Imatinib.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The monoclonal anti-VEGF antibody bevacizumab has been approved for the treatment of stage IV colorectal cancer.
The tyrosine kinase inhibitor imatinib mesylate has been shown to efficiently target PDGF-signalling.
Blocking PDGFR-signalling leads to disruption of pericytes from the endothelium and reverses the maturation status thereby enhancing the sensitivity to anti-VEGF therapy.This background forms a rationale for a combined therapeutic PDGF and VEGF inhibition.
Since bevacizumab shows best activity when used in combination with chemotherapy, capecitabine and oxaliplatin are included in this protocol.
Patients with stage IV colorectal cancer and no prior chemotherapy can enter the study.
Patients receive oral imatinib once a day on days 1-21.
Oral Capecitabine is given on days 1-14 bid, Oxaliplatin and Bevacizumab are given on day 1.
Courses are repeated every 22 days in the absence of disease progression or unacceptable toxicity.
Study Type
Interventional
Enrollment (Actual)
51
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Esslingen, Germany, 73730
- Städische Kliniken Esslingen
-
Leipzig, Germany, 04129
- Klinikum St. Georg gGmbH
-
Mainz, Germany, 55131
- Johannes-Gutenberg-Universität Mainz
-
Mannheim, Germany, 68167
- Klinikum Mannheim
-
Recklinghausen, Germany, 45659
- Prosper-Hospital
-
Schweinfurt, Germany, 97422
- Leopoldina Krankenhaus
-
Ulm, Germany, 89081
- Universitätsklinik Ulm
-
-
NRW
-
Cologne, NRW, Germany, 50937
- Medical Clinic for Haematology and Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically proven inoperable colorectal cancer
- Adult patients >= 18 years of age
- ECOG <2
Exclusion Criteria:
- Preceding chemo- or immunotherapy with the exception of adjuvant or neoadjuvant treatment of non-metastatic disease ending ≥ 6 month prior to study inclusion. Progression within 6 month after the end of adjuvant therapy must be excluded.
- Other malignancies with the exception of basal cell carcinoma or successfully treated carcinoma in situ of the cervix uteri.
- No history of severe comorbidities, i. e. uncontrolled hypertension, GI-bleeding, congestive heart-failure NYHA class II-IV, symptomatic coronary heart disease, myocardial infarction within 1 year prior to study inclusion, serious cardiac arrhythmias requiring medication, Grade II or greater peripheral vascular disease and other severe uncontrolled co-morbidities
- No history of stroke or other CNS-diseases (tumors, seizure, transient ischemic attack etc.)
- ≥ Grade II peripheral artery vascular occlusive disease
- Preexisting neuropathy ≥ Grade 1
- Interstitial pneumonia or lung fibrosis
- Serious, nonhealing wound, ulcer, or bone fracture
- Preceding irradiation an indicator lesion except for documented progressive disease during irradiation and termination of irradiation ≥ 4 weeks from study inclusion
- Thromboembolic or bleeding events within the last 6 month
- Need for therapeutic anticoagulation (heparin, cumarin)
- Use of ASS > 325 mg/die or NSAR
- Proteinuria > 1+ (stix) as long as urine protein >1g/24h
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: XELOX, Bevacizumab, Imatinib
|
Dose level I: Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg Repeat on day 22. Dose level II: Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg Repeat on day 22.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose limiting toxicity.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of overall response rate and progression free survival.
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ulrich Hacker, PD Dr., University Cologne
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
November 3, 2008
First Submitted That Met QC Criteria
November 3, 2008
First Posted (Estimate)
November 4, 2008
Study Record Updates
Last Update Posted (Estimate)
January 7, 2013
Last Update Submitted That Met QC Criteria
January 4, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Capecitabine
- Oxaliplatin
- Bevacizumab
- Imatinib Mesylate
Other Study ID Numbers
- AIO KRK 0205
- ML20344
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Colorectal Cancer
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingColorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E MutationUnited States
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditionsUnited States
Clinical Trials on Oxaliplatin, Capecitabine, Bevacizumab, Imatinib
-
Hebei Medical UniversityUnknownGastric Cancer | Liver MetastasisChina
-
Grupo Espanol Multidisciplinario del Cancer DigestivoUnknownMetastatic Colorectal CancerSpain
-
Dutch Colorectal Cancer GroupSanofi; Roche Pharma AGTerminatedColorectal Cancer | Liver MetastasesNetherlands
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingMetastatic Colorectal Cancer | Microsatellite Stable | RAS MutationChina
-
Geriatric Oncology ConsortiumSanofiTerminatedNeoplasm Metastasis | Colorectal CancerUnited States
-
Radboud University Medical CenterUnknownLiver Neoplasms | Colorectal NeoplasmsNetherlands
-
Hoffmann-La RocheCompleted
-
Cancer Institute and Hospital, Chinese Academy...RecruitingBevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutatedChina
-
Dutch Colorectal Cancer GroupSanofi; Roche Pharma AG; Koningin Wilhelmina Fonds; ImmuniconCompletedColorectal CancerNetherlands
-
Hoffmann-La RocheCompleted